Navigation Links
Medication effective for acute liver failure in early stages of disease
Date:10/7/2009

DALLAS Oct. 8, 2009 The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.

Acute liver failure occurs when cells in the liver die quickly, resulting in toxins being released into the bloodstream and brain. Patients often end up in a hepatic coma as a result of toxins not being cleared by the failing liver. Known causes of acute liver failure include autoimmune hepatitis, drug-induced liver injury, hepatitis A and B, and acetaminophen poisoning.

In a study published in the September issue of Gastroenterology, researchers found that acute liver failure patients in early stages of hepatic comas, when treated with the medicine N-acetylcysteine (NAC), were nearly 2.5 times more likely to survive than those treated only with a placebo.

"NAC is safe, easy to administer, doesn't require intensive care and can be given in community hospitals," said Dr. William M. Lee, professor of internal medicine at UT Southwestern and lead author of the study. "NAC is an excellent treatment for non-acetaminophen acute liver failure if the disease is caught early."

Acute liver failure affects about 2,000 people annually in the U.S., and 50 percent of those cases are caused by acetaminophen poisoning. Until this study, liver transplantation was the only treatment if the failure was from non-acetaminophen causes.

To test NAC's use in non-acetaminophen cases, researchers at 22 sites randomly assigned non-acetaminophen acute liver failure patients by the level of their coma, with those with mild to moderate coma in one group, and patients with more severe coma in the other group. Beginning in 1999 and continuing for eight years, 173 patients received either NAC or a placebo for 72 hours. Doctors recorded patient survival three weeks after they were placed on treatment.

Researchers found that 52 percent of acute liver failure patients in mild to moderate comas survived when treated with NAC, compared to just 30 percent of those treated with only a placebo. In patients experiencing more severe coma, treatment with NAC did not result in a significant difference in survival rates.

"That makes sense because patients with advanced comas typically die or get a transplant within a few days," said Dr. Lee, principal investigator of the Acute Liver Failure Study Group, a national consortium of liver centers formed in 1997 to increase research into the rare disease.

"This study establishes NAC as a treatment for non-acetaminophen acute liver failure patients in mild to moderate coma and provides the first glimmer of hope that something can help these direly ill patients," Dr. Lee said.

He said he will continue to study NAC as a therapy for acute liver failure not caused by acetaminophen poisoning to determine optimal dosing and duration.


'/>"/>

Contact: LaKisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Many Kids Suffer Medication Side Effects: Study
2. New Source of Information on Eczema Medications
3. Diabetes Medications Dont Lower Inflammation
4. Patients Get Free Text or Email Prescription Medication Reminders From FreeRxReminder.com
5. Medications That Lower Breast Cancer Risk Carry Other Dangers
6. Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate
7. Center for Technology and Aging Releases Guidelines for $500,000 Medication Optimization Diffusion Grants Program
8. CVS Caremark Data Finds More than 50 Percent of Adults 45-years and Younger are not Adherent to Cholesterol Lowering Medications
9. Medication Review May Help With Heart Failure
10. Misuse of Pain Medication Draws Heightened Concerns
11. Digitek Medication Recalled Due to Risk of Digitalis Toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medication effective for acute liver failure in early stages of disease
(Date:4/29/2016)... ... 2016 , ... The Gluten-Free Certification Program (GFCP), in partnership ... launch of the GFCP Scoop in response to consumer demand for ... GFCP Scoop site is to keep the gluten-free community updated about ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media ... on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy ... CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated ...
(Date:4/29/2016)... Westlake Village, CA (PRWEB) , ... April 29, ... ... Greater Philadelphia Pet Expo to promote their animal line of probiotics, Petbiotics ... to see the large turnout of animal rescue groups networking for their non-profit ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/26/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) is ... , Pharm D., to Vice President of Education and ... Hagerman will continue to lead and oversee Diplomat University, ... education and training to Diplomat employees and external professionals ... University also houses the quality assurance department, which focuses ...
Breaking Medicine Technology: